4D Molecular Therapeutics Inc’s recently made public that its Chief Legal Officer Bizily Scott unloaded Company’s shares for reported $0.26 million on Apr 01 ’24. In the deal valued at $31.78 per share,8,153 shares were sold. As a result of this transaction, Bizily Scott now holds 1,737 shares worth roughly $49938.75.
Then, Bizily Scott sold 5,833 shares, generating $204,410 in total proceeds. Upon selling the shares at $35.04, the Chief Legal Officer now owns 1,737 shares.
Before that, Bizily Scott sold 1,750 shares. 4D Molecular Therapeutics Inc shares valued at $54,722 were divested by the Chief Legal Officer at a price of $31.27 per share. As a result of the transaction, Bizily Scott now holds 1,737 shares, worth roughly $49938.75.
A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late October with a ‘”an Outperform”‘ rating. Cantor Fitzgerald began covering FDMT with “an Overweight” recommendation on October 24, 2023. Leerink Partners revised its rating on October 18, 2023. It rated FDMT as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of FDMT
On Monday, 4D Molecular Therapeutics Inc [NASDAQ:FDMT] saw its stock jump 0.52% to $28.75. Over the last five days, the stock has lost -4.20%. 4D Molecular Therapeutics Inc shares have risen nearly 41.91% since the year began. Nevertheless, the stocks have risen 78.46% over the past one year. While a 52-week high of $36.25 was reached on 03/27/24, a 52-week low of $9.44 was recorded on 01/19/24. SMA at 50 days reached $28.11, while 200 days put it at $18.68. A total of 0.56 million shares were traded, compared to the trading of 0.66 million shares in the previous session.
Levels Of Support And Resistance For FDMT Stock
The 24-hour chart illustrates a support level at 28.16, which if violated will result in even more drops to 27.57. On the upside, there is a resistance level at 29.30. A further resistance level may holdings at 29.86. The Relative Strength Index (RSI) on the 14-day chart is 46.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.04, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.21%. Stochastics %K at 14.96% indicates the stock is a buying.
How much short interest is there in 4D Molecular Therapeutics Inc?
A steep rise in short interest was recorded in 4D Molecular Therapeutics Inc stocks on Mar 15, 2024, growing by 1.44 million shares to a total of 8.5 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 7.06 million shares. There was a rise of 16.94%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 21.34% of the overall stock float, the days-to-cover ratio (short ratio) rose to 10.54.
The most recent change occurred on July 05, 2023 when Chardan Capital Markets began covering the stock and recommended ‘”a Buy”‘ rating along with a $30 price target.
